English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Deflazacort is a methyl-oxazoline derivative of prednisolone used for its anti-inflammatory and immunosuppressive effects. It is an inactive prodrug which is converted rapidly to its active metabolite 21- desacetyl deflazacort. A simple, rapid, sensitive and specific liquid chromatography-tandem mass spectrometry method was developed for the estimation of 21-desacetyl deflazacort in human plasma. Sample preparation involved simple solid phase extraction of 21-desacetyl deflazacort and internal standard. The samples were analyzed using a reversed phase column and detected using positive mode ESI tandem mass spectrometry. The LLOQ was 0.5 ng/mL and the assay was linear over the range of 0.5-100 ng/mL using a sample volume of 250µL. The method was validated for specificity, linearity, precision, accuracy and stability parameters. The method was applied to the analysis of plasma samples after oral administration of 6 mg DFZ tablets of marketed product in healthy adult subjects in a fasting bioavailability study.

A LC-MS/MS METHOD FOR THE QUANTIFICATION OF DEFLAZACORT METABOLITE IN HUMAN PLASMA: DEVELOPMENT, VALIDATION AND APPLICATION TO A PHARMACOKINETIC STUDY